Moderna Inc. Faces Stock Market Turmoil

In a dramatic turn of events, Moderna Inc. saw its shares drop by over 13% during Monday's premarket trading. This significant downturn comes in the wake of the resignation of Peter Marks, the Food and Drug Administration's (FDA) leading vaccine official.

The Resignation That Shook the Market

According to a spokesperson from the Department of Health and Human Services, Marks was given an ultimatum: resign or face termination. Sources close to the situation revealed to NBC News that the Trump administration was behind the forced departure of the FDA's vaccine division leader.

Market Reaction

By 7:36 am ET, Moderna's stock price had fallen to $26.76 per share, marking a 13.56% decrease. This event highlights the volatile nature of the stock market, especially in response to high-profile resignations within regulatory bodies.